Translational Development Acquisition Corp. watched its second-quarter profit fall sharply year over year, as net income dropped 41.7% to $946,982.
The blank-check firm, which maintains no operating revenue, posted diluted earnings per share of $0.04 for the period, down from $0.07 in the same quarter of 2025. Six-month results told a similar story. Net income for the first half of 2026 reached $2,279,779, a decline of 26.6% from $3,106,416 a year ago.
Meanwhile, the company pressed forward on a major transaction. It signed a definitive merger pact with ProLogium and launched a two-step process to bring the battery maker public.
To fund the deal, TDAC lined up a $50 million subscription involving 5 million shares plus warrants. That capital commitment hinges on closing one day prior to the first merger step.
The trust account also saw activity. Investors redeemed $27.8 million, while the company deposited $400,000 to push its deal deadline to August 24, 2026. If needed, extensions can stretch as far as June 24, 2027.
With no operating income, the company relied on interest generated by the trust to cover general and administrative costs and due diligence expenses tied to the pending merger.
The filing lands as special purpose acquisition companies face heightened scrutiny over deal timelines and redemption trends. Whether the ProLogium combination survives investor redemptions remains the central question heading into the extension window.
